An agent that selectively binds to and activates beta-adrenergic receptors.
| Member | Definition | Class |
|---|
| albuterol | A member of the class of phenylethanolamines that is 4-(2-amino-1-hydroxyethyl)-2-(hydroxymethyl)phenol having a tert-butyl group attached to the nirogen atom. It acts as a beta-adrenergic agonist used in the treatment of asthma and chronic obstructive pulmonary disease (COPD). | albuterol |
| apraclonidine | An imidazoline that is 2-amino 4,5-dihydro-1H-imidazoline in which one of the exocyclic amino hydrogens has been replaced by a 4-amino-2,6-dichlorophenyl group. | apraclonidine |
| arbutamine | | arbutamine |
| arformoterol | An N-[2-hydroxy-5-(1-hydroxy-2-{[1-(4-methoxyphenyl)propan-2-yl]amino}ethyl)phenyl]formamide in which both of the stereocentres have R configuration. The active enantiomer of formoterol, it is administered by inhalation (generally as the tartrate salt) as a direct-acting sympathomimetic and bronchodilator for the treatment of chronic obstructive pulmonary disease (any progressive respiratory disease that makes it harder to breathe over time, such as chronic bronchitis and emphysema). | arformoterol |
| bambuterol | A carbamate ester that is terbutaline in which both of the phenolic hydroxy groups have been protected as the corresponding N,N-dimethylcarbamates. A long acting beta-adrenoceptor agonist used in the treatment of asthma, it is a prodrug for terbutaline. | bambuterol |
| bambuterol hydrochloride | The hydrochloride salt of bambuterol. A long acting beta-adrenoceptor agonist used in the treatment of asthma, it is a prodrug for terbutaline. | bambuterol hydrochloride |
| berotek | A member of the class resorcinols that is 5-(1-hydroxyethyl)benzene-1,3-diol in which one of the methyl hydrogens is replaced by a 1-(4-hydroxyphenyl)propan-2-amino group. A beta2-adrenergic agonist, it is used (as the hydrobromide salt) as a bronchodilator in the management of reversible airway obstruction. | fenoterol |
| bitolterol | The di-4-toluate ester of (+-)-N-tert-butylnoradrenaline (colterol). A pro-drug for colterol, a beta2-adrenergic receptor agonist, bitolterol is used as its methanesulfonate salt for relief of bronchospasm in conditions such as asthma, chronic bronchitis and emphysema. | bitolterol |
| clenbuterol | A substituted aniline that is 2,6-dichloroaniline in which the hydrogen at position 4 has been replaced by a 2-(tert-butylamino)-1-hydroxyethyl group. | clenbuterol |
| colterol | A member of the class of ethanolamines that is catechol in which the hydrogen at position 4 is replaced by a 2-(tert-butylamino)-1-hydroxyethyl group. | colterol |
| diazoxide | A benzothiadiazine that is the S,S-dioxide of 2H-1,2,4-benzothiadiazine which is substituted at position 3 by a methyl group and at position 7 by chlorine. A peripheral vasodilator, it increases the concentration of glucose in the plasma and inhibits the secretion of insulin by the beta- cells of the pancreas. It is used orally in the management of intractable hypoglycaemia and intravenously in the management of hypertensive emergencies. | diazoxide |
| dobutamine | A catecholamine that is 4-(3-aminobutyl)phenol in which one of the hydrogens attached to the nitrogen is substituted by a 2-(3,4-dihydroxyphenyl)ethyl group. A beta1-adrenergic receptor agonist that has cardiac stimulant action without evoking vasoconstriction or tachycardia, it is used as the hydrochloride to increase the contractility of the heart in the management of acute heart failure. | dobutamine |
| dobutamine hydrochloride | The hydrochloride salt of dobutamine. A beta1-adrenergic receptor agonist that has cardiac stimulant action without evoking vasoconstriction or tachycardia, it is used to increase the contractility of the heart in the management of acute heart failure. | dobutamine hydrochloride |
| fenoterol | The hydrobromide salt of fenoterol. A beta2-adrenergic agonist, it is used as a bronchodilator in the management of reversible airway obstruction. | fenoterol hydrobromide |
| indacaterol | A monohydroxyquinoline that consists of 5-[(1R)-2-amino-1-hydroxyethyl]-8-hydroxyquinolin-2-one having a 5,6-diethylindan-2-yl group attached to the amino function. Used as the maleate salt for treatment of chronic obstructive pulmonary disease. | indacaterol |
| isoproterenol | A secondary amino compound that is noradrenaline in which one of the hydrogens attached to the nitrogen is replaced by an isopropyl group. A sympathomimetic acting almost exclusively on beta-adrenergic receptors, it is used (mainly as the hydrochloride salt) as a bronghodilator and heart stimulant for the management of a variety of cardiac disorders. | isoprenaline |
| L-isoprenaline | An optically active phenylethanolamine compound having an isopropyl substituent attached to the nitrogen atom. | L-isoprenaline |
| methoxyphenamine | An amphetamine methylated on nitrogen and with the phenyl ring methoxylated at C-2. A beta-adrenergic receptor agonist, it is used as a bronchodilator. | methoxyphenamine |
| mirabegron | A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 2-amino-1,3-thiazol-4-ylacetic acid with the anilino group of (1R)-2-{[2-(4-aminophenyl)ethyl]amino}-1-phenylethanol. Used for the treatment of overactive bladder syndrome. | mirabegron |
| nab-365 | A hydrochloride that is the monohydrochloride salt of clenbuterol. | clenbuterol hydrochloride |
| olodaterol | A member of the class of benzoxazine that is 6-hydroxy-1,4-benzoxazin-3-one in which the hydrogen at position 4 is replaced by a (1R)-1-hydroxy-2-{[1-(4-methoxyphenyl)-2-methylpropan-2-yl]amino}ethyl group. Used (as its hydrochloride salt) for long-term treatment of airflow obstruction in patients with chronic obstructive pulmonary disease including chronic bronchitis and/or emphysema. | olodaterol |
| solabegron | A carboxybiphenyl that is [biphenyl]-3-carboxylic acid carrying a (2-{[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino}ethyl)nitrilo group at the 3' position. A selective beta3-adrenergic receptor agonist currently in clinical development for the treatment of overactive bladder and irritable bowel syndrome. | solabegron |
| terbutaline | A member of the class of phenylethanolamines that is catechol substituted at position 5 by a 2-(tert-butylamino)-1-hydroxyethyl group. | terbutaline |
| vilanterol | An dichlorobenzene derivative that is used in the form of its trifenate salt for treatment of chronic obstructive pulmonary disease. | vilanterol |
| Protein | Taxonomy | Measurement | Average (mM) | Bioassay(s) | Drugs |
|---|
| 15-hydroxyprostaglandin dehydrogenase [NAD(+)] isoform 1 | Homo sapiens (human) | Potency | 39.8107 | 1 | 1 |
| 2,3-bisphosphoglycerate-independent phosphoglycerate mutase | Leishmania major strain Friedlin | Potency | 28.8710 | 1 | 2 |
| activating transcription factor 6 | Homo sapiens (human) | Potency | 9.7405 | 1 | 3 |
| aldehyde dehydrogenase 1 family, member A1 | Homo sapiens (human) | Potency | 21.2596 | 1 | 3 |
| apical membrane antigen 1, AMA1 | Plasmodium falciparum 3D7 | Potency | 10.0000 | 1 | 1 |
| AR protein | Homo sapiens (human) | Potency | 30.8279 | 5 | 5 |
| aryl hydrocarbon receptor | Homo sapiens (human) | Potency | 26.6032 | 1 | 1 |
| arylsulfatase A | Homo sapiens (human) | Potency | 17.4790 | 1 | 3 |
| ATAD5 protein, partial | Homo sapiens (human) | Potency | 1.8349 | 1 | 1 |
| Ataxin-2 | Homo sapiens (human) | Potency | 17.3715 | 2 | 5 |
| ATP-dependent phosphofructokinase | Trypanosoma brucei brucei TREU927 | Potency | 6.7252 | 1 | 6 |
| ATPase family AAA domain-containing protein 5 | Homo sapiens (human) | Potency | 4.6829 | 2 | 3 |
| beta-2 adrenergic receptor | Homo sapiens (human) | Potency | 5.3852 | 4 | 10 |
| caspase-3 | Cricetulus griseus (Chinese hamster) | Potency | 33.4915 | 1 | 1 |
| Caspase-7 | Cricetulus griseus (Chinese hamster) | Potency | 33.4915 | 1 | 1 |
| Cellular tumor antigen p53 | Homo sapiens (human) | Potency | 17.4124 | 1 | 2 |
| Chain A, 2-oxoglutarate Oxygenase | Homo sapiens (human) | Potency | 17.0453 | 1 | 4 |
| Chain A, Beta-lactamase | Escherichia coli K-12 | Potency | 9.0872 | 1 | 3 |
| Chain A, Ferritin light chain | Equus caballus (horse) | Potency | 0.2239 | 1 | 1 |
| Chain A, HADH2 protein | Homo sapiens (human) | Potency | 4.8605 | 2 | 7 |
| Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASE | Homo sapiens (human) | Potency | 24.5676 | 1 | 2 |
| Chain A, Putative fructose-1,6-bisphosphate aldolase | Giardia intestinalis | Potency | 6.9740 | 1 | 2 |
| Chain A, TYROSYL-DNA PHOSPHODIESTERASE | Homo sapiens (human) | Potency | 25.1189 | 1 | 1 |
| Chain B, HADH2 protein | Homo sapiens (human) | Potency | 4.8605 | 2 | 7 |
| chromobox protein homolog 1 | Homo sapiens (human) | Potency | 71.0761 | 2 | 6 |
| cytochrome P450 2C19 precursor | Homo sapiens (human) | Potency | 19.9526 | 1 | 1 |
| cytochrome P450 2C9, partial | Homo sapiens (human) | Potency | 19.4971 | 1 | 1 |
| cytochrome P450 2D6 | Homo sapiens (human) | Potency | 19.4770 | 1 | 7 |
| cytochrome P450 2D6 isoform 1 | Homo sapiens (human) | Potency | 7.9433 | 1 | 1 |
| cytochrome P450 3A4 isoform 1 | Homo sapiens (human) | Potency | 24.0870 | 2 | 10 |
| cytochrome P450 family 3 subfamily A polypeptide 4 | Homo sapiens (human) | Potency | 2.7995 | 1 | 4 |
| cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_a | Homo sapiens (human) | Potency | 33.4915 | 1 | 1 |
| D(1A) dopamine receptor | Homo sapiens (human) | Potency | 1.3127 | 1 | 4 |
| D(1A) dopamine receptor | Sus scrofa (pig) | Potency | 18.4927 | 1 | 1 |
| DNA polymerase kappa isoform 1 | Homo sapiens (human) | Potency | 16.8336 | 1 | 1 |
| dopamine D1 receptor | Homo sapiens (human) | Potency | 3.4991 | 1 | 3 |
| endonuclease IV | Escherichia coli | Potency | 25.1189 | 1 | 1 |
| estrogen nuclear receptor alpha | Homo sapiens (human) | Potency | 10.7802 | 4 | 5 |
| estrogen receptor 2 (ER beta) | Homo sapiens (human) | Potency | 31.6704 | 2 | 2 |
| estrogen-related nuclear receptor alpha | Homo sapiens (human) | Potency | 2.7155 | 5 | 17 |
| euchromatic histone-lysine N-methyltransferase 2 | Homo sapiens (human) | Potency | 16.5130 | 1 | 9 |
| EWS/FLI fusion protein | Homo sapiens (human) | Potency | 20.5295 | 4 | 8 |
| farnesoid X nuclear receptor | Homo sapiens (human) | Potency | 16.7842 | 1 | 1 |
| flap endonuclease 1 | Homo sapiens (human) | Potency | 8.4368 | 1 | 1 |
| Fumarate hydratase | Homo sapiens (human) | Potency | 2.2387 | 1 | 1 |
| G | Vesicular stomatitis virus | Potency | 19.4971 | 1 | 1 |
| GABA theta subunit | Rattus norvegicus (Norway rat) | Potency | 24.0870 | 1 | 5 |
| GALC protein | Homo sapiens (human) | Potency | 0.7079 | 1 | 1 |
| Gamma-aminobutyric acid receptor subunit alpha-1 | Rattus norvegicus (Norway rat) | Potency | 24.0870 | 1 | 5 |
| Gamma-aminobutyric acid receptor subunit alpha-2 | Rattus norvegicus (Norway rat) | Potency | 24.0870 | 1 | 5 |
| Gamma-aminobutyric acid receptor subunit alpha-3 | Rattus norvegicus (Norway rat) | Potency | 24.0870 | 1 | 5 |
| Gamma-aminobutyric acid receptor subunit alpha-4 | Rattus norvegicus (Norway rat) | Potency | 24.0870 | 1 | 5 |
| Gamma-aminobutyric acid receptor subunit alpha-5 | Rattus norvegicus (Norway rat) | Potency | 24.0870 | 1 | 5 |
| Gamma-aminobutyric acid receptor subunit alpha-6 | Rattus norvegicus (Norway rat) | Potency | 24.0870 | 1 | 5 |
| Gamma-aminobutyric acid receptor subunit beta-1 | Rattus norvegicus (Norway rat) | Potency | 24.0870 | 1 | 5 |
| Gamma-aminobutyric acid receptor subunit beta-2 | Rattus norvegicus (Norway rat) | Potency | 24.0870 | 1 | 5 |
| Gamma-aminobutyric acid receptor subunit beta-3 | Rattus norvegicus (Norway rat) | Potency | 24.0870 | 1 | 5 |
| Gamma-aminobutyric acid receptor subunit delta | Rattus norvegicus (Norway rat) | Potency | 24.0870 | 1 | 5 |
| Gamma-aminobutyric acid receptor subunit epsilon | Rattus norvegicus (Norway rat) | Potency | 24.0870 | 1 | 5 |
| Gamma-aminobutyric acid receptor subunit gamma-1 | Rattus norvegicus (Norway rat) | Potency | 24.0870 | 1 | 5 |
| Gamma-aminobutyric acid receptor subunit gamma-2 | Rattus norvegicus (Norway rat) | Potency | 24.0870 | 1 | 5 |
| Gamma-aminobutyric acid receptor subunit gamma-3 | Rattus norvegicus (Norway rat) | Potency | 24.0870 | 1 | 5 |
| Gamma-aminobutyric acid receptor subunit pi | Rattus norvegicus (Norway rat) | Potency | 24.0870 | 1 | 5 |
| geminin | Homo sapiens (human) | Potency | 10.6866 | 3 | 11 |
| GLI family zinc finger 3 | Homo sapiens (human) | Potency | 10.7268 | 2 | 3 |
| glp-1 receptor, partial | Homo sapiens (human) | Potency | 2.5121 | 2 | 10 |
| GLS protein | Homo sapiens (human) | Potency | 8.5302 | 2 | 13 |
| glucokinase regulatory protein | Homo sapiens (human) | Potency | 19.7020 | 1 | 2 |
| GTP-binding nuclear protein Ran isoform 1 | Homo sapiens (human) | Potency | 3.4620 | 1 | 2 |
| Guanine nucleotide-binding protein G | Homo sapiens (human) | Potency | 7.0795 | 1 | 1 |
| heat shock 70kDa protein 5 (glucose-regulated protein, 78kDa) | Homo sapiens (human) | Potency | 23.2809 | 1 | 1 |
| hexokinase-4 isoform 1 | Homo sapiens (human) | Potency | 19.7020 | 1 | 2 |
| Histamine H2 receptor | Cavia porcellus (domestic guinea pig) | Potency | 19.9526 | 1 | 2 |
| histone acetyltransferase KAT2A isoform 1 | Homo sapiens (human) | Potency | 39.8107 | 1 | 2 |
| Histone H2A.x | Cricetulus griseus (Chinese hamster) | Potency | 52.6340 | 2 | 5 |
| HLA class I histocompatibility antigen, B alpha chain | Homo sapiens (human) | Potency | 19.4971 | 1 | 1 |
| huntingtin isoform 2 | Homo sapiens (human) | Potency | 35.4813 | 1 | 1 |
| hypoxia-inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor) | Homo sapiens (human) | Potency | 0.2767 | 2 | 6 |
| IDH1 | Homo sapiens (human) | Potency | 29.0929 | 1 | 1 |
| importin subunit beta-1 isoform 1 | Homo sapiens (human) | Potency | 3.4620 | 1 | 2 |
| Inositol hexakisphosphate kinase 1 | Homo sapiens (human) | Potency | 19.4971 | 1 | 2 |
| Interferon beta | Homo sapiens (human) | Potency | 26.3956 | 2 | 2 |
| lamin isoform A-delta10 | Homo sapiens (human) | Potency | 13.3848 | 2 | 7 |
| M-phase phosphoprotein 8 | Homo sapiens (human) | Potency | 37.0529 | 1 | 3 |
| Microtubule-associated protein tau | Homo sapiens (human) | Potency | 6.9456 | 2 | 3 |
| mitogen-activated protein kinase 1 | Homo sapiens (human) | Potency | 4.0875 | 2 | 5 |
| muscarinic acetylcholine receptor M1 | Rattus norvegicus (Norway rat) | Potency | 28.1838 | 1 | 1 |
| neuropeptide S receptor isoform A | Homo sapiens (human) | Potency | 6.3096 | 1 | 1 |
| NFKB1 protein, partial | Homo sapiens (human) | Potency | 9.9396 | 2 | 6 |
| nuclear factor erythroid 2-related factor 2 isoform 1 | Homo sapiens (human) | Potency | 17.1492 | 1 | 2 |
| nuclear receptor ROR-gamma isoform 1 | Mus musculus (house mouse) | Potency | 12.5893 | 1 | 1 |
| nuclear receptor subfamily 1, group I, member 3 | Homo sapiens (human) | Potency | 21.5226 | 2 | 4 |
| parathyroid hormone/parathyroid hormone-related peptide receptor precursor | Homo sapiens (human) | Potency | 2.0484 | 1 | 2 |
| peripheral myelin protein 22 | Rattus norvegicus (Norway rat) | Potency | 4.5221 | 1 | 4 |
| peripheral myelin protein 22 isoform 1 | Homo sapiens (human) | Potency | 60.1198 | 1 | 1 |
| peroxisome proliferator activated receptor gamma | Homo sapiens (human) | Potency | 26.8325 | 1 | 1 |
| phosphopantetheinyl transferase | Bacillus subtilis | Potency | 44.9793 | 1 | 5 |
| plasminogen precursor | Mus musculus (house mouse) | Potency | 7.9433 | 1 | 1 |
| polyprotein | Zika virus | Potency | 2.2387 | 1 | 1 |
| Polyunsaturated fatty acid lipoxygenase ALOX15B | Homo sapiens (human) | Potency | 19.9526 | 1 | 1 |
| potassium voltage-gated channel subfamily H member 2 isoform d | Homo sapiens (human) | Potency | 3.5481 | 1 | 1 |
| pregnane X nuclear receptor | Homo sapiens (human) | Potency | 29.8493 | 1 | 1 |
| Rap guanine nucleotide exchange factor 4 | Homo sapiens (human) | Potency | 11.2202 | 1 | 1 |
| RAR-related orphan receptor gamma | Mus musculus (house mouse) | Potency | 22.6384 | 2 | 4 |
| regulator of G-protein signaling 4 | Homo sapiens (human) | Potency | 15.6682 | 1 | 8 |
| retinoic acid nuclear receptor alpha variant 1 | Homo sapiens (human) | Potency | 29.8493 | 2 | 2 |
| retinoid X nuclear receptor alpha | Homo sapiens (human) | Potency | 13.9844 | 2 | 2 |
| serine/threonine-protein kinase mTOR isoform 1 | Homo sapiens (human) | Potency | 18.2885 | 2 | 3 |
| SMAD family member 2 | Homo sapiens (human) | Potency | 23.9145 | 1 | 1 |
| SMAD family member 3 | Homo sapiens (human) | Potency | 23.9145 | 1 | 1 |
| Smad3 | Homo sapiens (human) | Potency | 0.7079 | 1 | 1 |
| snurportin-1 | Homo sapiens (human) | Potency | 3.4620 | 1 | 2 |
| Spike glycoprotein | Severe acute respiratory syndrome-related coronavirus | Potency | 28.1838 | 1 | 1 |
| survival motor neuron protein isoform d | Homo sapiens (human) | Potency | 1.5849 | 1 | 1 |
| TDP1 protein | Homo sapiens (human) | Potency | 20.5138 | 2 | 12 |
| thioredoxin reductase | Rattus norvegicus (Norway rat) | Potency | 10.7310 | 3 | 14 |
| thyroid hormone receptor beta isoform a | Homo sapiens (human) | Potency | 6.3096 | 1 | 1 |
| thyroid stimulating hormone receptor | Homo sapiens (human) | Potency | 3.8199 | 5 | 31 |
| transcriptional regulator ERG isoform 3 | Homo sapiens (human) | Potency | 22.7798 | 1 | 2 |
| urokinase plasminogen activator surface receptor precursor | Mus musculus (house mouse) | Potency | 7.9433 | 1 | 1 |
| urokinase-type plasminogen activator precursor | Mus musculus (house mouse) | Potency | 7.9433 | 1 | 1 |
| USP1 protein, partial | Homo sapiens (human) | Potency | 25.2941 | 2 | 4 |
| v-jun sarcoma virus 17 oncogene homolog (avian) | Homo sapiens (human) | Potency | 6.3157 | 2 | 2 |
| vitamin D (1,25- dihydroxyvitamin D3) receptor | Homo sapiens (human) | Potency | 5.3538 | 1 | 1 |
| vitamin D3 receptor isoform VDRA | Homo sapiens (human) | Potency | 56.4541 | 1 | 3 |